Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
DP1 inhibitor
Laropiprant is used in combination with niacin to reduce blood cholesterol. Laropiprant acts as a DP1 antagonist, reducing the vasodilation. -
Thromboxane A2 synthesis inhibitor
Ozagrel is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor. -
Prostaglandin Receptor inhibitor
Benorilate, also known as Win-11450, is an ester of aspirin and paracetamol with analgesic, antipyretic, and anti-inflammatory activity used in the treatment of rheumatoid diseases. Benorilate has less severe side effects than aspirin. -
Prostaglandin Receptor inhibitor
Dinoprost Tromethamine, also known as Dinoprost Trometamol, is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient. -
LTC4 inhibitor
Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2). -
prostaglandin synthase inhibitor
Pizuglanstat is a hematopoietic prostaglandin synthase inhibitor. -
Prostaglandin E2 Inhibitor
Thielavin B is an inhibitor of prostaglandin biosynthesis, specifically targeting the synthesis of prostaglandin E2 from endoperoxide precursors. This compound demonstrates significant anti-inflammatory activity, as evidenced by its efficacy in reducing carrageenan-induced edema in rat models following intravenous administration. Thielavin B is valuable for research focused on inflammation and pain pathways. -
PGDS Inhibitor
2-Benzoylthiophene is a selective inhibitor of human hematopoietic prostaglandin D2 synthase (H-PGDS), exhibiting an IC50 value of 11.4 μM. This compound is valuable for investigating the role of prostaglandin D2 in inflammatory diseases and related research applications. Its inhibitory action on H-PGDS provides a useful tool for exploring therapeutic strategies targeting inflammatory pathways. -
Prostaglandin Receptor Inhibitor
p-Hydroxycinnamic acid is a prostaglandin receptor inhibitor that functions as a dietary phenolic compound. It demonstrates significant biological activity by inhibiting platelet activity, with IC50 values of 371 μM for thromboxane B2 production and 126 μM for lipopolysaccharide-induced prostaglandin E2 generation. This compound is often utilized in research related to inflammation, cardiovascular diseases, and platelet function studies. -
Dual Thromboxane Synthase Inhibitor and Receptor Antagonist
Ridogrel is a dual thromboxane A2 synthase inhibitor and receptor antagonist. This compound exhibits potent antiplatelet activity, making it useful in research focused on cardiovascular diseases and thrombotic disorders. Additionally, Ridogrel displays anti-inflammatory properties, providing a valuable tool for studying inflammation-related pathways in various biological contexts. -
Prostaglandin Receptor Inhibitor
Ascorbyl tetra-2-hexyldecanoate is a lipophilic derivative of L-ascorbic acid that functions as a prostaglandin receptor inhibitor. This compound demonstrates protective effects on HaCaT keratinocytes, maintaining cell viability against UVB and oxidative stress while decreasing the production of inflammatory mediators IL-1α and prostaglandin E2 (PGE2). In vivo studies show that topical application enhances epidermal thickness, increases stratum corneum hydration, and improves skin texture, highlighting its potential for formulating skin whitening agents in cosmetic applications. -
TxA2 Synthase/Receptor Inhibitor
Picotamide is a dual inhibitor of thromboxane A2 (TxA2) synthase and its receptor, exhibiting significant antiplatelet activity. This compound is effective in reducing microalbuminuria and inhibiting the growth of carotid plaques, particularly in diabetic models. Picotamide is a valuable tool for investigating both acute and chronic cardiovascular diseases, aiding research into therapeutic interventions for these conditions. -
EP2 Inhibitor
TG8-260 is a selective EP2 antagonist designed to mitigate the effects of inflammation in both central nervous system and peripheral diseases. This compound effectively reduces neuroinflammation and gliosis in the hippocampus of rats following pilocarpine-induced status epilepticus. With a plasma half-life of 2.14 hours and an oral bioavailability of 77.3%, TG8-260 also demonstrates potent inhibition of CYP450. Its ability to inhibit EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia makes it a valuable tool for investigating anti-inflammatory pathways in various animal models of peripheral inflammatory conditions. -
Thromboxane Synthase Inhibitor
Dazoxiben hydrochloride is a potent thromboxane synthase inhibitor that exhibits oral bioavailability. It effectively suppresses thromboxane production, a key factor in platelet aggregation and vascular smooth muscle contraction. This compound is utilized in research focused on cardiovascular diseases and conditions related to thrombosis and inflammation. -
Thromboxane Synthase Inhibitor
Furegrelate sodium is a selective thromboxane synthase inhibitor, demonstrating significant inhibition of human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. This compound is being investigated for its potential as an antiplatelet agent, making it a valuable tool for research in cardiovascular diseases and platelet function studies. Its oral availability enhances its applicability in preclinical and clinical settings, contributing to advancements in antiplatelet therapy development. -
PGHS1 Inhibitor
Satigrel is a selective inhibitor of prostaglandin H synthase 1 (PGHS1), primarily targeting platelet aggregation. It effectively inhibits collagen- and arachidonic acid-induced platelet aggregation by blocking thromboxane A2 synthesis. With an IC50 of 0.081 μM for PGHS1 and 5.9 μM for PGHS2, Satigrel also demonstrates inhibitory activity against Type III, Type V, and Type II phosphodiesterases, with IC50 values of 15.7 μM, 39.8 μM, and 62.4 μM, respectively. This compound is valuable for research into platelet function and thrombotic diseases. -
Prostaglandin E2 Inhibitor
Thielavin A is a selective inhibitor of prostaglandin E2 biosynthesis, derived from the fungus Thielavia terricola. It specifically targets the conversion of arachidonic acid to prostaglandin H2, thereby disrupting the prostaglandin synthesis pathway. Despite its inhibition of prostaglandin E2, Thielavin A exhibits minimal anti-inflammatory effects upon intravenous or oral administration, making it a valuable tool for studying prostaglandin-related biological processes and inflammation research. -
sPLA2 Inhibitor
CAY10590 is a potent inhibitor of secreted phospholipase A2 (sPLA2), serving as a valuable tool for investigating the role of sPLA2 in chronic inflammatory kidney diseases. Its mechanism of action enables the modulation of inflammatory pathways, which is critical for understanding disease mechanisms and potential therapeutic interventions. This compound is applicable in preclinical research aimed at elucidating the involvement of sPLA2 in renal pathologies. -
PTGR2 Inhibitor
HHS-0701 is a potent inhibitor of prostaglandin reductase 2 (PTGR2), functioning as a sulfur-triazole exchange (SuTEx) ligand. This compound effectively blocks the metabolism of the lipid substrate 15-Keto-PGE2 by PTGR2, playing a crucial role in modulating prostaglandin levels. HHS-0701 is valuable for research applications involving inflammation and lipid metabolism, providing insights into the enzymatic regulation of prostaglandins. -
Prostaglandin Inhibitor
Ibuprofen guaiacol ester is a potent inhibitor of prostaglandin synthesis, demonstrating significant oral bioactivity. It is primarily utilized in research related to inflammation, edema, and fever modulation. This compound provides valuable insights into the mechanistic pathways of pain and inflammatory responses, making it a useful tool in pharmacological studies. -
Prostaglandin Metabolism Inhibitor
L11204 is a potent inhibitor of prostaglandin metabolism. It effectively inhibits PMS-induced superovulation, resulting in a reduced number of recoverable ova in the oviducts of hamsters. Additionally, L11204 demonstrates the capability to inhibit chorionic gonadotrophin-induced ovarian hypertrophy and steroidogenesis in rats. This compound shows promise for studying reproductive system disorders and related biological processes. -
Prostaglandin Receptor Inhibitor
1,2,3-Trilinoelaidoyl glycerol acts as a prostaglandin receptor inhibitor, influencing the biosynthesis of prostaglandins and modulating platelet function. This compound also demonstrates significant effects on the fatty acid composition within rat organs, depending on the dosage administered. It serves as a valuable tool for examining dietary impacts on lipid metabolism and associated physiological parameters in preclinical research involving rodent models. -
Thromboxane Synthase Inhibitor
Furegrelate is a selective thromboxane synthase inhibitor that acts primarily by blocking the synthesis of thromboxane A2 (TxA2) in human platelets, exhibiting an IC50 of 15 nM. Its potent inhibitory action makes Furegrelate a valuable candidate for research applications focused on antiplatelet therapies. This compound is under investigation for its potential to mitigate thrombotic events associated with cardiovascular diseases. -
Thromboxane Synthetase Inhibitor
UK 34787 is a selective thromboxane synthetase inhibitor that exhibits minimal activity against cyclooxygenase and prostacyclin synthetase. This compound is utilized in research to study thromboxane's role in cardiovascular function and various pathophysiological conditions. Its specificity makes it a valuable tool in investigating the therapeutic potential of thromboxane modulation in disease models. -
Thromboxane Synthase Inhibitor
Wy 27569 is a thromboxane synthase inhibitor that modulates prostaglandin balance by decreasing pro-thrombotic thromboxane A2 (TXA2) and increasing anti-thrombotic prostacyclin (PGI2). This compound is known for its vascular selectivity and ability to effectively lower blood pressure. Wy 27569 is utilized in research on cardiovascular diseases, including hypertension and angina, making it valuable for understanding thrombotic processes and vascular health. -
Thromboxane A2 Synthetase Inhibitor
Nafagrel hydrochloride is a potent thromboxane A2 synthetase inhibitor. This compound effectively prevents thrombus formation, demonstrated in a rat model of acute arterial thrombosis. It is valuable for research applications related to cardiovascular disease, thrombosis, and related therapeutic interventions. -
Thromboxane Synthetase Inhibitor
Dazoxiben is an effective thromboxane synthetase inhibitor that functions to reduce thromboxane production, thereby influencing platelet aggregation and vasoconstriction. This compound is particularly relevant in the investigation of vascular conditions, such as Raynaud's syndrome, where thromboxane overproduction may play a critical role. Its oral bioavailability makes it suitable for in vivo studies on thromboxane-related pathologies. -
PGHS-2 Inhibitor
15(S)-HpEPE is a lipoxygenase-derived hydrolysis product of polyunsaturated fatty acids (PUFAs), serving as a potential inhibitor of prostaglandin H synthase 2 (PGHS-2). This compound has been shown to downregulate PGHS-2 expression, making it a valuable tool for research focused on inflammatory pathways and associated diseases. Its biological activity is of interest in studies examining the modulation of prostaglandin synthesis and the regulation of inflammatory responses. -
PTGR2 Inhibitor
RJG-2036 is a potent covalent inhibitor of human prostaglandin reductase 2 (PTGR2) with an IC50 value of 100 nM. This compound effectively inhibits NADPH-dependent reduction, leading to a significant decrease in the secretion of proinflammatory cytokines such as TNF-α and various eicosanoids in LPS-stimulated THP-1 macrophages. RJG-2036 serves as a valuable tool for investigating the molecular mechanisms underlying inflammatory diseases. -
TxA2 Synthase/Receptor Inhibitor
Picotamide monohydrate is a dual inhibitor of thromboxane A2 (TxA2) synthase and its receptor, exhibiting significant antiplatelet activity. This compound has been shown to reduce microalbuminuria and inhibit the progression of carotid plaques in diabetic models. Picotamide monohydrate serves as a valuable tool for investigating both acute and chronic cardiovascular diseases in research settings. -
Prostaglandin E2 Inhibitor
Seprilose is a potent inhibitor of prostaglandin E2 synthesis, acting primarily by targeting the relevant enzymatic pathways involved in its production. This compound demonstrates significant anti-inflammatory activity, making it valuable for research applications focused on inflammation and related disorders. Seprilose can be utilized in studies examining the role of prostaglandins in various physiological and pathological processes. -
Thromboxane Synthase Inhibitor
Imitrodast is a selective thromboxane synthase inhibitor, effectively blocking the conversion of arachidonic acid to thromboxane A2. This compound demonstrates significant activity in modulating bronchoconstriction and possesses potential applications in research related to respiratory disorders and cardiovascular diseases. Its mechanism may help elucidate the role of thromboxane in various pathological conditions. -
Thromboxane Synthase Inhibitor
Rolafagrel is a selective inhibitor of thromboxane synthase, a key enzyme involved in the synthesis of thromboxane A2, which plays a pivotal role in platelet aggregation and vascular contraction. This compound has significant implications in cardiovascular research, facilitating the study of thromboxane-mediated pathways and their contribution to various cardiovascular disorders. Its use may aid in the development of therapeutic strategies targeting thromboxane-related conditions. -
DP2 Receptor Inhibitor
CRTh2 antagonist 4 is a selective inhibitor of the DP2 receptor, displaying an IC50 value of 212 nM and a binding affinity with a Ki of 37 nM. This compound is useful in the investigation of TH2 lymphocyte-related pathways and has potential applications in understanding and treating severe allergic diseases. -
Thromboxane Synthase Inhibitor
Imitrodast sodium is a potent thromboxane synthase inhibitor. This compound plays a significant role in research related to bronchoconstriction and its associated pathways. Its ability to inhibit thromboxane production offers insights into the mechanisms of allergic reactions and pulmonary function, making it valuable for studies focused on respiratory health and related conditions. -
TXA2 Receptor Inhibitor
BM-531 is a dual-action thromboxane receptor (TXA2) inhibitor that also functions as a thromboxane synthase inhibitor. This compound demonstrates significant anti-aggregatory effects on human citrated platelet-rich plasma, effectively inhibiting arachidonic acid-induced aggregation with an ED100 of 0.125 μM and U-46619-induced aggregation with an ED50 of 0.482 μM. Additionally, BM-531 is shown to inhibit contraction in porcine uterine smooth muscle induced by high potassium levels, making it a valuable tool for research in thrombosis and uterine contractility studies. -
Cyclooxygenase Inhibitor
KC-764 is an orally active, reversible inhibitor of cyclooxygenase, preferentially targeting platelet cyclooxygenase. It effectively reduces platelet thromboxane A2 (TXA2) production and inhibits platelet aggregation, exhibiting IC50 values of 0.23 μM and 26 nM, respectively. This compound is valuable for research focused on antiplatelet therapy and the prevention of recurrence in ischemic stroke. -
TXA2 Inhibitor
(E/Z)-Ozagrel sodium is a selective thromboxane A2 (TXA2) synthase inhibitor, exhibiting an IC50 value of 11 nM. By inhibiting TXA2 production, it promotes vasodilation and exhibits anti-platelet aggregation and anti-inflammatory effects through increased prostacyclin (PGI2) levels. This reagent is valuable for research into ischemic stroke, asthma, and thromboembolic diseases. -
FP/TP Receptor Inhibitor
CAY10535 is an inhibitor of the FP and TP receptors, targeting key pathways involved in cardiovascular function. This compound demonstrates potential for elucidating the role of these receptors in cardiovascular disease pathology. It serves as a valuable tool for researchers investigating therapeutic interventions aimed at modulating prostanoid signaling in cardiovascular conditions. -
Prostaglandin Receptor Inhibitor
Iso-Samixogrel is a potent prostaglandin receptor inhibitor, functioning as both a thromboxane A2 receptor blocker and a thromboxane synthetase inhibitor. This compound demonstrates significant antithrombotic activity by effectively preventing recurrent arterial thrombus formation and inhibiting collagen-induced platelet aggregation in ex vivo studies. Additionally, Iso-Samixogrel prolongs sublingual bleeding time, indicating its potential utility in the management of thrombotic disorders. -
TXA2 Inhibitor
Isbogrel is a selective inhibitor of thromboxane A2 (TXA2) synthase, demonstrating potent activity in reducing TXA2 generation in the bloodstream. With an ID50 value of 0.04 mg/kg, Isbogrel exhibits effective oral bioavailability. This compound is primarily utilized in research focused on cardiovascular diseases and thrombotic disorders, contributing to the understanding of TXA2's role in platelet aggregation and vascular functions. -
Thromboxane Synthase Inhibitor
LG 82-4-00 is a selective thromboxane synthase inhibitor with an IC50 of 1.1 μM. This compound effectively inhibits collagen-induced formation of TXB2 and subsequently reduces platelet aggregation in plasma. LG 82-4-00 serves as a valuable tool in research focused on thrombotic disorders, contributing to the understanding of thromboxane's role in vascular biology and pathology. -
Platelet Inhibitor
Prostaglandin D3 (PGD3) is a natural prostaglandin that functions as an inhibitor of platelet aggregation. Its primary biological activity involves modulation of autonomic neurotransmission. PGD3 is utilized in research to study cardiovascular diseases and platelet activity, making it a valuable reagent for investigations into thrombosis and related conditions. -
Prostaglandin D Synthase Inhibitor
Pizuglanstat hydrate is a potent inhibitor of prostaglandin D synthase, exhibiting an IC50 of 76 nM for human hematopoietic prostaglandin D synthase. This compound effectively inhibits the synthesis of prostaglandin D2, making it relevant in research into inflammatory conditions. Pizuglanstat hydrate has demonstrated efficacy in improving experimental allergic rhinitis and offers potential applications in the study of muscle regenerative diseases, including muscular dystrophy. -
Prostaglandin Receptor Inhibitor
RS-61756-007 is a selective thromboxane receptor (TP) agonist that exhibits high affinity and activity specifically at the TP receptor. In vitro studies demonstrate that RS-61756-007 also shows agonistic effects at FP receptors, while remaining inactive against other receptor subtypes. The biological effects of RS-61756-007 can be effectively inhibited by the TP antagonist SQ 29,548. This compound is valuable for research aimed at understanding thromboxane signaling and its implications in various physiological and pathological processes. -
Thromboxane Synthetase Inhibitor
Y-20811 sodium is a selective thromboxane synthetase inhibitor that exhibits potent and irreversible inhibition of thromboxane A2 synthesis. This compound is primarily utilized in cardiovascular research, particularly in studying thrombosis and its associated pathophysiological mechanisms. Its oral bioactivity makes it a valuable tool for investigating therapeutic interventions in thromboxane-related vascular disorders. -
Thromboxane Inhibitor
BM567 is a potent thromboxane A2 receptor (TXR) antagonist and thromboxane A2 synthase (TXS) inhibitor, with IC50 values of 1.1 nM and 12 nM, respectively. This sulfonylurea compound demonstrates significant antithrombogenic activity, making it a valuable tool for studying thromboxane signaling pathways in various biological contexts. Its application extends to research on cardiovascular diseases and the role of thromboxane in platelet aggregation and vasoconstriction. -
Thromboxane A2 Receptor Inhibitor
Samixogrel is a potent thromboxane A2 receptor inhibitor that modulates thromboxane synthesis. Its mechanism of action involves blocking the thromboxane A2 signaling pathway, which is crucial for platelet aggregation and vascular constriction. This compound is primarily utilized in research related to cardiovascular disease and thrombotic disorders, providing valuable insights into the role of thromboxane A2 in pathophysiological processes. -
Prostaglandin Receptor Inhibitor
15(S)-Latanoprost is a potent agonist of prostaglandin receptors, exhibiting reduced activity compared to its parent compound, latanoprost. In a binding assay utilizing cat iris sphincter muscle, 15(S)-latanoprost demonstrated an IC50 value of 24 nM. Furthermore, administration of 3 μg of 15(S)-latanoprost resulted in a measurable decrease in intraocular pressure (IOP) by 1 mmHg in normotensive cynomolgus monkeys. This compound is valuable for research into ocular conditions and the modulation of intraocular pressure.
